Neumora Therapeutics

Company snapshot

We develop miRNA-based therapies that address the root causes of neurological diseases. This goes far beyond the limitations of current treatment options, which only manage individual symptoms.

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 US patent(s) indexed to this assignee profile.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Neumora Therapeutics. Not investment advice.

• Peer + 0 momentum

  Cognition Therapeutics

  TA overlap score 26.6

Recent activity

Latest pipeline, patent, and corporate events for Neumora Therapeutics.

1. Jun 8, 2026 Clinical update

   NMRA-335140-303 — Phase 3

2. Jun 5, 2026 Clinical update

   NMRA-323511 — Phase 1

3. May 26, 2026 Clinical update

   NMRA-335140 — Phase 3

4. May 23, 2026 Clinical update

   NMRA-335140 — Phase 3

5. May 23, 2026 Clinical update

   NMRA-335140 80 mg — Phase 2

View all clinical trial activity →

• What is Neumora Therapeutics?

  Neumora Therapeutics is a biotech organization headquartered in copenhagen, DK. It trades on NYSE under ticker NMRA. Primary therapeutic focus areas include Major Depressive Disorder, Alzheimer's Disease, Major Depressive Episode Associated With Bipolar II Disorder. NovaPharmaNew

• Is Neumora Therapeutics publicly traded?

  Yes. Neumora Therapeutics is listed with ticker NMRA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Neumora Therapeutics develop or market?

  We link 2 drug profile(s) where Neumora Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/neumora-therapeutics#company-drugs.

• What are the latest developments for Neumora Therapeutics?

  In the last 12 months our linked public records show 5 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Neumora Therapeutics focus on?

  Neumora Therapeutics focuses on Major Depressive Disorder, Alzheimer's Disease, Major Depressive Episode Associated With Bipolar II Disorder based on our analysis of their pipeline programs and drug development activities.